SGMT Sagimet Biosciences Inc. Series A Common Stock

XNAS 9.56 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

SGMT $9.56 —
Key stats
$9.56
Pre-market $9.60 +0.42%
52-Week Range
$4.50 – $11.45
YTD
+59.60%
IV Rank (30D)
60.0
Straddle Price
$1.82
P/C Vol Ratio
0.16
Market Cap
$0.7B
Open
$9.61
Day Range
$9.41 – $9.70
Volume
767,188
Prev Close
$9.58
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY2.43
Cost of Equity (CAPM)18.31% (VRP-adj)
WACC18.52%
Volatility Risk Premium+43.8pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-18.4%
Book / Price71.1% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$9.94 (Market Anchor value)
SMA 20 / Bollinger Mid$9.02
Bollinger Width / SMA20330.8% (drives anchor stability)
Net Debt$-0.2B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$23.87
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.2× · 3 peers
Peer P/B $23.87 100% median 3.5× · 3 peers
Peer P/S n/a 0% median 3.9× · 3 peers
Market Anchor (SMA50) $9.94 0% stability 0% (BB-width)
Options Expected (B-L 30d) $9.39 0% 8 strikes · skew +0.16
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.7B
Employees
16
List Date
2023-07-14
CIK
0001400118
Next Earnings
2026-11-12 (Pre-Market)
EPS Forecast
($0.25) (4 est.)
Headquarters
Foster City, CA
Homepage
https://www.sagimet.com

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development …

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'23'24'25'26Avg
Jan--77.86%-2.00%-5.34%23.51%
Feb---38.70%-20.28%-8.35%-22.44%
Mar---9.97%-5.51%-8.65%-8.04%
Apr---25.43%33.72%53.24%20.51%
May--29.68%-9.67%-4.20%5.27%
Jun---33.98%118.34%7.51%30.62%
Jul0.00%6.33%8.22%-4.05%2.62%
Aug-24.55%-11.49%-8.97%43.50%-0.38%
Sep-26.67%-6.42%-6.79%-5.90%-11.45%
Oct-51.97%65.06%22.06%2.03%*9.29%
Nov7.61%6.75%-10.42%--1.31%
Dec43.01%-16.04%-12.94%--4.68%
Total-59.10%-18.35%70.18%65.35%14.52%
* Only 4 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $9.02
SMA 50: $9.94
SMA 200: $7.41
Current: $9.56
EMA 12: $9.26
EMA 26: $9.33
MACD: -0.0708 | Signal: 0.1743
BEARISH
ADX (14): 19.16
RANGE
+DI: 28.08
−DI: 20.81

Momentum Oscillators

RSI (14): 52.42
NEUTRAL
Stoch %K: 80.99
Stoch %D: 85.39
Williams %R: -24.07

Volume & Volatility

BB Upper: $10.37
BB Lower: $7.68
NEUTRAL
OBV: 92,095,607
Vol SMA 20: 1,555,707
Vol ROC: -33.72%
ATR: $0.62
True Range: $0.29
HV 20: 83.5%
HV 30: 86.9%
HV 60: 76.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10) Key Drivers and Primary Risks: + Technical drivers: Strong momentum signal from MACD, positive RSI reading + Primary risks: High volatility, potential for market sell-off affecting stock price 2-3 sentence investment thesis: SGMT is a volatile stock with a strong technical signal, but its high beta and recent price movements suggest caution. The options market is pricing in a moderate move ahead of expiration, while the news sentiment remains positive. Recent News Sentiment Impact: Positive news headlines have contributed to the recent price increase, but the overall news sentiment has been neutral.

Technical Analysis

Trend Direction: Short-term: Uptrend (SMA 20 > Current Price), Medium-term: Range-bound (SMA 50 and EMA 12 around current price) Support/Resistance Levels: Upper Bollinger Band ($8.09) and recent high ($7.43) serve as resistance, while the lower band ($6.77) serves as support. Momentum Signals: + RSI interpretation: Neutral (46.13), not overbought or oversold + MACD signal: Bullish (0.12 / Signal: -0.05 / Histogram: 0.16) + Bollinger Bands position: Squeeze, with price near the middle band Volume Analysis: Volume SMA 20 is declining (-44.41%), suggesting a potential distribution event.

News & Sentiment Analysis

Recent Headlines Summary: The news headlines are generally positive, focusing on company updates and participation in investor conferences. Sentiment Assessment: Positive sentiment dominates (3/5), with some neutral headlines mixed in. Catalyst Identification: Participation in upcoming investor conferences may provide additional catalysts for the stock price.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta > 1.2) Volatility Regime: Current volatility is high, but not historically extreme Options Market Signals: + IV rank: Low (7.5%) + Put/Call volume ratio: Bearish sentiment (2.93) + Put/Call OI ratio: Neutral (1.16) Downside Protection: Support levels are around $6.77, and the options market is pricing in a moderate move ahead of expiration.

Market Context & Positioning

Sector Performance: SGMT is outperforming its sector peers in recent weeks. Institutional Activity: Volume patterns suggest some institutional interest, but not overwhelming. Correlation Analysis: The stock moves relatively independently of the market (R-squared interpretation). Relative Valuation: The stock is trading within a range, with no clear overvaluation or undervaluation.

Key Levels & Action Items

Critical Price Levels: $6.77 (support) and $8.09 (resistance) Breakout/Breakdown Levels: A close above $7.43 could trigger an uptrend, while a close below $6.60 could lead to a decline. Time-Sensitive Catalysts: Participation in upcoming investor conferences may provide additional catalysts for the stock price. Risk Management: Consider using stop-loss levels around $6.77 and position sizing considerations based on market conditions.

Note: This report provides an objective analysis of the stock, highlighting both bullish and bearish cases. The confidence level is moderate (6/10) due to the high volatility and potential for market sell-offs affecting the stock price.

Generated
Earnings History
9 of 9 under expected move
Avg Expected Move
18.57%
Avg Actual Move
5.21%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-14 Pre-Market 16.92% 7.14% 0.42x Within
2024-11-14 Pre-Market 19.93% 13.95% 0.70x Within
2025-03-12 Pre-Market 29.46% 3.39% 0.12x Within
2025-05-08 Pre-Market 30.69% 4.19% 0.14x Within
2025-08-13 Pre-Market 7.33% 0.31% 0.04x Within
2025-11-13 Pre-Market 20.41% 12.24% 0.60x Within
2026-03-11 Pre-Market 18.54% 3.80% 0.20x Within
2026-05-12 Pre-Market 10.73% 0.52% 0.05x Within
2026-08-12 Pre-Market 13.13% 1.37% 0.10x Within

Earnings calendar: this week’s reports with expected vs actual moves →

SGMT Options Activity & IV Rank

SGMT IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 88.9%
7-DTE IV: —
Expected Move: $1.82
7-DTE Move: $1.82
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 255
Put Volume: 42
P/C Volume: 0.165
BULLISH
Call OI: 764
Put OI: 5,801
P/C OI: 7.593
Total OI: 6,565

ATM Options Pricing

ATM Call: $0.70
ATM Put: $1.12
Call %: 7.3%
Put %: 11.8%

Chain Summary

Chain Volume: 1,273
Chain OI: 14,901
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 1st percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
1%
vs own history
GEX tilt
-0.78
OI-weighted, today
Vanna tilt
-0.73
δ-sensitivity to IV
Charm tilt
+0.82
δ-decay vs time
Vanna tilt -0.73: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.82: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 6 ATM contracts, 6k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 87.0% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)60.0MediumOct 26
Straddle Price (30 DTE)$1.82Oct 26
Beta Analysis

Risk Metrics

Beta: 1.8694
Alpha: 11.83%
Correlation: 0.2906
R-Squared: 8.4%
Stock Volatility: 82.0%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SGMT
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$7.2M
0.00%
#1817 of 3716+8.7%13F
Renaissance Technologies Hedge fund
Jim Simons
$2.7M
0.00%
#1808 of 3138-44.5%13F
Citadel Hedge fund
Ken Griffin
$809K
0.00%
#3942 of 6285+53.5%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

SGMT Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 37,666,406 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

131 filers52,383,977 shares$403.00M value139.07% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 6,575,788 $50.83M 12.61% 17.46% 2026-06-30
2 Balyasny Asset Management L.P. 3,626,113 $28.03M 6.96% 9.63% 2026-06-30
3 Woodline Partners LP 3,000,652 $23.20M 5.76% 7.97% 2026-06-30
4 SILVERARC CAPITAL MANAGEMENT, LLC 2,927,698 $22.63M 5.62% 7.77% 2026-06-30
5 Vanguard Capital Management LLC 2,566,272 $19.84M 4.92% 6.81% 2026-06-30
6 BVF INC/IL 2,500,000 $19.32M 4.80% 6.64% 2026-06-30
7 Caligan Partners LP 2,500,000 $19.32M 4.80% 6.64% 2026-06-30
8 Affinity Asset Advisors, LLC 2,497,864 $19.31M 4.79% 6.63% 2026-06-30
9 FEDERATED HERMES, INC. 2,086,715 $16.13M 4.00% 5.54% 2026-06-30
10 GREAT POINT PARTNERS LLC 2,029,933 $15.69M 3.89% 5.39% 2026-06-30
11 State Street Corp 1,995,092 $15.42M 3.83% 5.30% 2026-06-30
12 Saturn V Capital Management LP 1,479,918 $11.44M 2.84% 3.93% 2026-06-30
13 Geode Capital Management, LLC Custodian 1,444,019 $11.17M 2.77% 3.83% 2026-06-30
14 Blue Owl Capital Holdings LP 1,260,544 $9.74M 2.42% 3.35% 2026-06-30
15 Vanguard Group Inc Custodian 1,259,550 $7.46M 1.85% 3.34% 2025-12-31
16 BAKER BROS. ADVISORS LP 952,996 $7.37M 1.83% 2.53% 2026-06-30
17 Millennium Management LLC Custodian 937,025 $7.24M 1.80% 2.49% 2026-06-30
18 Aberdeen Group plc 847,700 $6.55M 1.63% 2.25% 2026-06-30
19 Goldman Sachs Group Inc Custodian 759,086 $5.87M 1.46% 2.02% 2026-06-30
20 HHLR ADVISORS, LTD. 724,800 $5.60M 1.39% 1.92% 2026-06-30
21 Ameriprise Financial, Inc. Custodian 581,217 $4.49M 1.11% 1.54% 2026-06-30
22 Vestal Point Capital, LP 535,452 $4.14M 1.03% 1.42% 2026-06-30
23 Northern Trust Corp Custodian 468,385 $3.62M 0.90% 1.24% 2026-06-30
24 BOOTHBAY FUND MANAGEMENT, LLC 464,095 $3.59M 0.89% 1.23% 2026-06-30
25 ADAR1 Capital Management, LLC 437,500 $3.38M 0.84% 1.16% 2026-06-30
6 filers$3.53M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $2.24M 63.30% 2026-06-30
2 GROUP ONE TRADING LLC Custodian $568.93K 16.11% 2026-06-30
3 Citadel Advisors LLC Custodian $397.32K 11.25% 2026-06-30
4 Simplex Trading, LLC Custodian $217.21K 6.15% 2026-06-30
5 Jane Street Group, LLC Custodian $112.86K 3.19% 2026-06-30
6 FNY Investment Advisers, LLC $0 0.00% 2026-09-30
5 filers$3.42M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $1.44M 42.19% 2026-06-30
2 Citadel Advisors LLC Custodian $1.04M 30.31% 2026-06-30
3 Jane Street Group, LLC Custodian $411.24K 12.04% 2026-06-30
4 Simplex Trading, LLC Custodian $353.26K 10.34% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $174.70K 5.12% 2026-06-30

SGMT Insider Trading (Form 4)

Latest: 2026-08-17
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-17 George Kemble Director Mixed — $8.30 -$1.36M EDGAR
2026-08-12 George Kemble Director Mixed — $8.16 -$72.6K EDGAR
2026-07-22 Elizabeth Rozek Chief Legal & Admin. Officer Sell (S) −10,545 $7.76 -$81.8K EDGAR
2026-07-22 David Happel President & CEO Sell (S) −64,051 $7.76 -$497.1K EDGAR
2026-07-22 George Kemble Director Sell (S) −18,844 $7.46 -$140.5K EDGAR
2026-06-15 Beth C Seidenberg Director Grant (A) +39,567 opt — EDGAR
2026-06-15 Paul W. Hoelscher Director Grant (A) +39,567 opt — EDGAR
2026-06-15 Anne M. Phillips Director Grant (A) +39,567 opt — EDGAR
2026-06-15 George Kemble Director Grant (A) +39,567 opt — EDGAR
2026-06-15 Jennifer Jarrett Director Grant (A) +39,567 opt — EDGAR
2026-06-15 Elizabeth A Grammer Director Grant (A) +39,567 opt — EDGAR
2026-06-01 Andreas Grauer Chief Medical Officer Grant (A) +35,000 opt — EDGAR
2026-06-01 David Happel President & CEO Grant (A) +300,000 opt — EDGAR
2026-06-01 Elizabeth Rozek Chief Legal & Admin. Officer Grant (A) +100,000 opt — EDGAR
2026-06-01 Thierry Chauche Chief Financial Officer Grant (A) +50,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

SGMT Insider Holdings

6 insiders · @ $9.56
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 David Happel President & CEO 741,570 $7.09M -$1.09M 11 2026-07-22
2 George Kemble Executive Chairman 413,148 $3.95M -$4.34M 11 2026-08-17
3 Elizabeth Rozek Chief Legal & Admin. Officer 224,414 $2.15M -$228.2K 10 2026-07-22
4 Eduardo Bruno Martins Chief Medical Officer 147,296 $1.41M -$121.0K 7 2026-02-20
5 Beth C Seidenberg Director 84,768 $810.4K $750.0K 4 2026-06-15
6 Thierry Chauche Chief Financial Officer 59,688 $570.6K -$7.0K 5 2026-06-01
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

SGMT Board & Officers

As of SEC filings through Aug 17, 2026

Directors 6

Officers 4

Changes in the last 10 years (45)
Jun 15, 2026George Kemble no longer listed as Executive Chairman in SEC filings
Jun 12, 2026The company announced the departure of Timothy P Walbert from the board in an SEC filing
Apr 20, 2026The company announced the departure of Eduardo Bruno Martins as Chief Medical Officer in an SEC filing
Apr 20, 2026Andreas Grauer became Chief Medical Officer
Nov 6, 2025Elizabeth Rozek listed as Chief Legal & Admin. Officer (previously General Counsel and CCO) in SEC filings
Jun 6, 2025The company announced the departure of Eduardo Bruno Martins from the board in an SEC filing
Jun 6, 2025The company announced the departure of David Happel from the board in an SEC filing
Apr 29, 2025The company announced the departure of Merdad Parsey from the board in an SEC filing
Aug 1, 2024Jennifer Jarrett became a director
Aug 1, 2024Anne M. Phillips became a director
May 6, 2024Thierry Chauche became Chief Financial Officer
May 5, 2024The company announced the departure of Joseph Oriti as officer in an SEC filing
Apr 1, 2024Timothy P Walbert became a director
Apr 1, 2024Paul W. Hoelscher became a director
Mar 20, 2024The company announced the departure of Richard J Rodgers from the board in an SEC filing
Mar 20, 2024The company announced the departure of Jinzi Jason Wu from the board in an SEC filing
Feb 1, 2024Joseph Oriti became an officer
Jan 31, 2024Scott D Sandell reported in an SEC filing no longer being a 10% owner
Jan 31, 2024Patrick J Kerins reported in an SEC filing no longer being a 10% owner
Jan 31, 2024New Enterprise Associates 13 LP reported in an SEC filing no longer being a 10% owner
Not reported recently (4)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

SGMT Proposed Insider Sales (Form 144)

Latest: 2026-08-14
Last 30d: 0 filings  ·  Last 90d: 2 filings · $3.5M notice value · 1 unique filer · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: GEORGE KEMBLE (2, $3.5M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-14 GEORGE KEMBLE Director 350,987 $3.26M 2026-08-14 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-11 GEORGE KEMBLE Director 20,206 $193.4K 2026-08-11 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-20 GEORGE KEMBLE Director, Officer 18,844 $147.4K 2026-07-20 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-11-20 GEORGE KEMBLE Director, Officer 37,688 $295.9K 2025-11-20 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-07-23 GEORGE KEMBLE Director, Officer 23,625 $73.0K 2024-07-23 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
35 ETFs hold SGMT
25 shown · $74.68M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $18.4M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.02% $14.2M $74.6B 2026-10-23
3 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.12% $12.8M $10.4B 2026-10-23
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $6.9M — 2026-09-30
5 IBB iShares Biotechnology ETF iShares (BlackRock) 0.04% $4.2M $10.7B 2026-10-23
6 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.03% $4.0M $13.7B 2026-10-23
7 VTWO Vanguard Russell 2000 ETF Vanguard 0.02% $3.4M — 2026-09-30
8 DFAS Dimensional US Small Cap ETF Dimensional 0.01% $2.5M — 2026-10-23
9 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.14% $1.7M $1.2B 2026-10-23
10 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $1.1M $13.9B 2026-10-23
11 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $970,100 $96.5B 2026-10-23
12 VFMO Vanguard U.S. Momentum Factor ETF Vanguard 0.04% $826,179 — 2026-10-23
13 DFMC Dimensional US Micro Cap ETF Dimensional 0.01% $697,654 — 2026-10-23
14 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.03% $501,163 — 2026-09-30
15 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.09% $500,651 — 2026-10-26
16 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $436,436 — 2026-10-23
17 DFUS Dimensional US Equity Market ETF Dimensional 0.00% $311,877 $21.7B 2026-10-23
18 RSSL Global X Russell 2000 ETF Global X 0.02% $270,166 — 2026-10-26
19 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $254,790 — 2026-10-23
20 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $243,207 $20.4B 2026-10-23
21 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.01% $116,278 — 2026-09-30
22 DFSU Dimensional US Sustainability Core 1 ETF Dimensional 0.00% $68,919 $2.4B 2026-10-23
23 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $49,281 — 2026-09-30
24 DFAU Dimensional US Core Equity Market ETF Dimensional 0.00% $49,078 $13.0B 2026-10-23
25 IBBQ Invesco Nasdaq Biotechnology ETF Invesco 0.04% $45,371 — 2026-10-24
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.28
TTM Revenue
—
TTM Net Income
$-47.08M
TTM Op. Cash Flow
$-41.72M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30—$-13.95M$-0.26$-11.10M
Q1 '262026-03-31—$-10.65M$-0.33$-8.61M
Q4 '252025-12-31—$-9.57M$-0.30$-11.83M
Q3 '252025-09-30—$-12.91M$-0.40$-10.18M
Q2 '252025-06-30—$-10.39M$-0.32$-9.10M
Q1 '252025-03-31—$-18.18M$-0.56$-14.54M
Q4 '242024-12-31—$-16.20M$-0.50$-11.02M
Q3 '242024-09-30—$-14.62M$-0.45$-19.57M
Q2 '242024-06-30—$-8.12M$-0.25$-5.63M
Q1 '242024-03-31—$-6.63M$-0.23$-6.21M
Q4 '232023-12-31$0.00$-8.15M$0.56$-7.08M
Q3 '232023-09-30$2.00M$-6.35M$-0.35$-3.88M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.41
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-18.4%
ROA
-17.9%
Div Yield
0.00%
FCF Yield
-11.59%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$360.09M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
11.19M
SI % of Float
20.59%
Days to Cover
6.70
Short Vol Ratio
67.3%
Free Float
54.34M
Float %
88.2%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22